1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Dry Age-related Macular Degeneration - Pipeline Insight, 2021

Dry Age-related Macular Degeneration - Pipeline Insight, 2021

  • July 2021
  • 100 pages
  • ID: 6124424
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

“Dry Age-related Macular Degeneration – Pipeline Insight, 2021,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Dry Age-related Macular Degeneration pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Dry Age-related Macular Degeneration Understanding

Dry Age-related Macular Degeneration: Overview
Age-related macular degeneration (AMD) is a degenerative disease of the center area of the ocular-posterior segment (the macula lutea) that causes slow degeneration in central vision and severe disability in affected persons. “Age-related” means that it mainly occurs with elderly adults, while “Macular” means that the macula part of the eye is damaged. AMD mostly affects people aged above 50, and it was first reported more than 80 years ago. Dry macular degeneration is a common eye disorder among people aged above 50 years. It causes blurred or reduced central vision due to thinning of the macula. The macula is the part of the retina responsible for clear vision in a direct line of sight. GA or choroidal neovascularization are two processes that produce photoreceptor failure in late AMD and can cause visual loss. Usually, dry AMD progresses very slowly whereas, some people experience severe visual impairment within days or weeks of the onset of wet AMD. The diagnostic methods of AMD include fundus imaging, fluorescein angiogenesis (FA), indocyanine green angiography (ICGA), optical coherence tomography (OCT), Optical coherence tomography angiography (OCTA), and artificial intelligence (AI). These techniques play an important role in the diagnosis of AMD and have their unique advantages. A detailed understanding of the molecular mechanisms underlying wet AMD has led to several robust FDA-approved therapies. In contrast, there are not any approved treatments for dry AMD. The management of dry AMD consists of observation, regular follow-up evaluations, and documentation for timely recognition of visual function deterioration with appropriate rehabilitation and early CNV detection.

"Dry Age-related Macular Degeneration - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dry Age-related Macular Degeneration pipeline landscape is provided which includes the disease overview and Dry Age-related Macular Degeneration treatment guidelines. The assessment part of the report embraces, in depth Dry Age-related Macular Degeneration commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dry Age-related Macular Degeneration collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Dry Age-related Macular Degeneration R&D. The therapies under development are focused on novel approaches to treat/improve Dry Age-related Macular Degeneration.

Dry Age-related Macular Degeneration Emerging Drugs Chapters
This segment of the Dry Age-related Macular Degeneration report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Dry Age-related Macular Degeneration Emerging Drugs
• ALK-001: Alkeus Pharmaceuticals
ALK-001 is once-a-day oral drug candidate currently being tested in Phase III clinical trial for the treatment of geographic atrophy (advanced form of AMD) and Stargardt disease. Toxic vitamin A aggregates called "dimers" are known to rapidly form due to a genetic defect in Stargardt, or to accumulate with age in the case of dry AMD. These toxic dimers have been implicated in the degeneration of the retina seen in Stargardt and AMD. Dimers form when two molecules of vitamin A are chemically combined. ALK-001 is form of vitamin A that has been chemically-modified to prevent its aggregation into dimers.

• Zimura: Iveric bio
Zimura (avacincaptad pegol) is an investigational drug product designed to target and inhibit the cleavage of complement protein C5 and the formation of its downstream fragments, C5a and C5b. By inhibiting the formation of these fragments, Zimura is believed to decrease or slow the chronic inflammation and cell death associated with the retinal aging process by decreasing the formation of membrane attack complex (MAC) and inflammasome activity, thereby potentially avoiding or slowing the degeneration of retinal pigment epithelial cells.

• Visomitin: Mitotech
Visomitin is an eye drop formulation of SkQ1 that has been developed to target ophthalmic disorders like dry eye syndrome, uveitis and age-related macular degeneration. SkQ1 - is a purposely designed cardiolipin peroxidation inhibitor. SkQ1 was developed to deliver a highly active antioxidant plastoquinone into mitochondria. Once positioned in mitochondria, the molecule acts as a mitochondria-targeted ROS scavenger in general and as a very efficient cardiolipin protector in particular.

• Risuteganib: Allegro Ophthalmics
Risuteganib is an investigational integrin-regulating therapy that is believed to reduce mitochondrial dysfunction involved in intermediate dry AMD. By targeting multiple pathways, risuteganib may help reduce the cellular burden of oxidative stress and restore retinal homeostasis. Two concurrent Phase 3 studies evaluating the use of intravitreal risuteganib to treat intermediate dry AMD are expected to begin within the next 12 months. A Phase II clinical trial evaluating risuteganib in Dry AMD has been completed by allegro Ophthalmics.

• GT005: Gyroscope Therapeutics
Gyroscope’s lead investigational gene therapy, GT005, is a one-time therapy delivered under the retina. An overactive complement system has been implicated in the development of AMD. GT005 is designed to restore balance to an overactive complement system, a part of the immune system, by increasing production of the CFI protein. The CFI protein regulates the activity of the complement system. It is believed that increasing CFI production will dampen the systems over activity and reduce inflammation, with the goal of preserving a person’s eyesight. Gyroscope’s lead candidate, GT005, is currently in two Phase IIs for patients with geographic atrophy, an irreversible degeneration of retinal cells caused by dry-AMD.

• GEM103: Gemini Therapeutics
Gemini’s lead program, GEM103, is a pioneering precision medicine approach, targeting trial enrichment with genetically-defined patients. GEM103 targets a genetically-defined subset of age-related macular degeneration (AMD) patients with complement dysregulation. GEM103 is believed to be the first ever recombinant native complement modulator, full-length recombinant complement factor H (rCFH) protein. When delivered by intravitreal injection, GEM103 has the potential to address unmet medical need in genetically-defined subsets of AMD patients by circumventing dysfunctional CFH loss-of-function variants and slowing the progression of their retinal disease. A Phase II clinical trial is currently being evaluated to treat patients with Dry AMD and other retinal disease.
Further product details are provided in the report……..

Dry Age-related Macular Degeneration: Therapeutic Assessment
This segment of the report provides insights about the different Dry Age-related Macular Degeneration drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Dry Age-related Macular Degeneration
There are approx. 40+ key companies which are developing the therapies for Dry Age-related Macular Degeneration. The companies which have their Dry Age-related Macular Degeneration drug candidates in the most advanced stage, i.e. Phase III include, Alkeus Pharmaceuticals.
• Phases
This report covers around 40+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Dry Age-related Macular Degeneration pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Dry Age-related Macular Degeneration: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dry Age-related Macular Degeneration therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dry Age-related Macular Degeneration drugs.

Dry Age-related Macular Degeneration Report Insights
• Dry Age-related Macular Degeneration Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Dry Age-related Macular Degeneration Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Dry Age-related Macular Degeneration drugs?
• How many Dry Age-related Macular Degeneration drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dry Age-related Macular Degeneration?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Dry Age-related Macular Degeneration therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Dry Age-related Macular Degeneration and their status?
• What are the key designations that have been granted to the emerging drugs?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

RNA Therapy Market Research Report by Technology, by Application, by End User, by State - United States Forecast to 2026 - Cumulative Impact of COVID-19

  • $ 2249 - $ 1912 - Get 15% off now!
  • September 2021
  • 89 pages

RNA Therapy Market Research Report by Technology (Enabled Technologies and Enabling Technologies), by Application (Cancer, Cardiovascular, and Genetic Disorders), by End User, by State (California, Florida, ...

  • United States
  • Genetic Disorder
  • Marketing Research
  • Industry analysis

ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on